Sherilyn McCoy - Novocure Director

NVCR Stock  USD 14.64  1.57  12.01%   

Director

Ms. Sherilyn D. McCoy is Independent Director of the Company. Ms. McCoy was chief executive officer of Avon Products, Inc., a direct selling company in beauty, household and personal care categories, from 2012 to 2018. Prior to joining Avon, Ms. McCoy had various roles at Johnson Johnson, most recently serving as vice chairman of the executive committee and member of the office of the chairman, where she was responsible for the pharmaceutical and consumer business divisions of the company. She brings substantial general business leadership and innovation knowledge and experience as a senior leader of two global Fortune 500 companies. Ms. McCoy holds a B.A. in textile chemistry from the University of Massachusetts, Dartmouth, a masters degree in chemical engineering from Princeton University, and an MBA from Rutgers University. Ms. McCoy is also a director of AstraZeneca, PLC and Stryker Corporationrationration. since 2018.
Age 59
Tenure 6 years
Address No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Phone44 15 3475 6700
Webhttps://www.novocure.com

Novocure Management Efficiency

The company has return on total asset (ROA) of (0.1209) % which means that it has lost $0.1209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5153) %, meaning that it created substantial loss on money invested by shareholders. Novocure's management efficiency ratios could be used to measure how well Novocure manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/28/2024, Return On Capital Employed is likely to drop to -0.25. In addition to that, Return On Assets is likely to drop to -0.19. At this time, Novocure's Non Current Assets Total are relatively stable compared to the past year. As of 03/28/2024, Non Currrent Assets Other is likely to grow to about 14.7 M, while Net Tangible Assets are likely to drop slightly above 267.8 M.
The company currently holds 596.24 M in liabilities with Debt to Equity (D/E) ratio of 1.31, which is about average as compared to similar companies. Novocure has a current ratio of 7.92, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Novocure until it has trouble settling it off, either with new capital or with free cash flow. So, Novocure's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novocure sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novocure to invest in growth at high rates of return. When we think about Novocure's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Mary HoeltzelCigna Corp
N/A
Kimberly RossCigna Corp
56
Paul GabosMednax Inc
55
Jane HenneyCigna Corp
69
Garheng KongLaboratory
45
James RogersCigna Corp
69
Alfred LimEUDA Health Holdings
72
Donna ZarconeCigna Corp
63
Gary GillilandLaboratory
63
George KurianCigna Corp
54
Dipchand NisharGuardant Health
N/A
TimothyCigna Corp
N/A
Samir KaulGuardant Health
44
Kerrii AndersonLaboratory
63
Robert WilliamsLaboratory
72
Sanders WilliamsLaboratory
69
John PartridgeCigna Corp
71
Bahija JallalGuardant Health
56
Peter NeupertLaboratory
65
Jeffrey DavisLaboratory
57
Stanley MeresmanGuardant Health
71
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. NovoCure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people. Novocure (NVCR) is traded on NASDAQ Exchange in USA. It is located in No. 4 The Forum, Saint Helier, Jersey, JE2 4UF and employs 1,453 people. Novocure is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Novocure Leadership Team

Elected by the shareholders, the Novocure's board of directors comprises two types of representatives: Novocure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novocure. The board's role is to monitor Novocure's management team and ensure that shareholders' interests are well served. Novocure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novocure's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Hung, Director
Sherilyn McCoy, Director
William Vernon, Independent Director
William Burke, Chief Officer
Frank Leonard, Executive Oncology
Asaf Danziger, CEO and Director
Kinyip Leung, Vice Chairman and Chairman of The Global Commercialization Team
Timothy Langloss, Independent Director
Piet MD, Head VP
Moshe Giladi, Chief Officer
Pr MD, Founder CTO
MBA MD, Chief Officer
Eilon Kirson, Chief Science Officer and Head of Research and Development
Todd Longsworth, General Counsel
Ingrid Goldberg, VP Relations
Charles Phillips, Independent Director
Louis Lavigne, Independent Director
Barak Arye, General Counsel
William Burkoth, Independent Director
Michael Ambrogi, COO
Martin Madden, Independent Director
Michael Puri, Chief Officer
Robert Mylod, Independent Director
Yoram Palti, CTO, Director
Uri MD, Chief Officer
Pritesh Shah, Chief Commercial Officer
Ashley Cordova, Chief Officer
Wilhelmus Groenhuysen, Chief Officer
Jeryl Hilleman, Director
Gert Perlhagen, Independent Director
Peter Melnyk, Chief Commercial Officer
William Doyle, Executive Chairman

Novocure Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novocure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novocure is a strong investment it is important to analyze Novocure's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novocure's future performance. For an informed investment choice regarding Novocure Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novocure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.
Note that the Novocure information on this page should be used as a complementary analysis to other Novocure's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Novocure Stock analysis

When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Global Correlations
Find global opportunities by holding instruments from different markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data
Money Managers
Screen money managers from public funds and ETFs managed around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Is Novocure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novocure. If investors know Novocure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novocure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.06)
Earnings Share
(1.95)
Revenue Per Share
4.787
Quarterly Revenue Growth
0.042
Return On Assets
(0.12)
The market value of Novocure is measured differently than its book value, which is the value of Novocure that is recorded on the company's balance sheet. Investors also form their own opinion of Novocure's value that differs from its market value or its book value, called intrinsic value, which is Novocure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novocure's market value can be influenced by many factors that don't directly affect Novocure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novocure's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novocure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novocure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.